A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma

Phase 1/2 Recruiting 43 enrolled Rznomics, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1/2a, open-label study to evaluate the safety, tolerability, immunogenicity, and preliminary clinical activity of RZ-001 administered in combination with VGCV in subjects with hTERT-positive GBM.

Timeline

Start: 2024-10-08
Primary completion: 2029-03
Completion: 2029-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RZ-001	Unknown	—	Intrathecal
Background	VGCV	Small molecule	—	Oral

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma

Summary

Timeline

Drugs

Indications